Abstract
Pain is a frequent and disabling symptom among multiple sclerosis (MS) and it is estimated to occur in 55% to 65% of patients. The mechanism of pain in MS has not yet been defined, because it can result from somatic, visceral, emotional, or neurologic impairment. The importance of this classification is related to different medical approaches to treat the pain in MS patients. In the management of symptomatic pain, new therapeutic strategies are now available to represent a great opportunity improving the quality of life. The availability of newer drugs for symptomatic treatment of pain in MS indicates a need to pay attention to this problem.
Keywords: Psychogenic Pain, Trigeminal neuralgia, Carbamazepine, Phenytoin, Lamotrigine, Tricyclic antidepressants, Cannabinoids
Current Clinical Pharmacology
Title: Drugs Treatment of Pain in Multiple Sclerosis
Volume: 2 Issue: 3
Author(s): Antonio Siniscalchi, Luca Gallelli and Giovambattista De Sarro
Affiliation:
Keywords: Psychogenic Pain, Trigeminal neuralgia, Carbamazepine, Phenytoin, Lamotrigine, Tricyclic antidepressants, Cannabinoids
Abstract: Pain is a frequent and disabling symptom among multiple sclerosis (MS) and it is estimated to occur in 55% to 65% of patients. The mechanism of pain in MS has not yet been defined, because it can result from somatic, visceral, emotional, or neurologic impairment. The importance of this classification is related to different medical approaches to treat the pain in MS patients. In the management of symptomatic pain, new therapeutic strategies are now available to represent a great opportunity improving the quality of life. The availability of newer drugs for symptomatic treatment of pain in MS indicates a need to pay attention to this problem.
Export Options
About this article
Cite this article as:
Siniscalchi Antonio, Gallelli Luca and De Sarro Giovambattista, Drugs Treatment of Pain in Multiple Sclerosis, Current Clinical Pharmacology 2007; 2 (3) . https://dx.doi.org/10.2174/157488407781668785
DOI https://dx.doi.org/10.2174/157488407781668785 |
Print ISSN 1574-8847 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3938 |
Related Articles
-
Subject Index to Volume 4
Current Drug Targets - Cardiovascular & Hematological Disorders Mutations in PRKN and SNCA Genes Important for the Progress of Parkinson’s Disease
Current Genomics Cardiovascular Diseases and the Nitric Oxide Pathway
Current Vascular Pharmacology Retraction Notice: Prevention of Emetic Episodes During Cesarean Delivery Performed Under Regional Anesthesia in Parturients
Current Drug Safety CB Receptor Ligands from Plants
Current Topics in Medicinal Chemistry Benzopyran Derivatives as Cardio-selective ATP-sensitive Potassium Channel Openers: A Review
Mini-Reviews in Medicinal Chemistry Neuroprotection by the α2-Adrenoceptor Agonist, Dexmedetomidine, in Experimental Stroke Models
Vascular Disease Prevention (Discontinued) Evolution of Antipsychotic Intervention in the Schizophrenic Psychosis
Current Drug Targets Oxidative-Nitrosative Stress In Hypertension
Current Vascular Pharmacology RAAS Inhibition and Renal Protection
Current Pharmaceutical Design A Systematic Review of Randomized Controlled Trials Examining the Nephroprotective Properties of Antihypertensive Medications
Current Hypertension Reviews The Renin Angiotensin System in the Regulation of Angiogenesis
Current Pharmaceutical Design Fibromyalgia: The Prototypical Central Sensitivity Syndrome
Current Rheumatology Reviews Developing Pharmacotherapies for Cannabis and Cocaine Use Disorders
Current Neuropharmacology The Etiology of Hypertension in the Metabolic Syndrome Part Four: The Systemic Perspective – The Role of the Neuroendocrine and Immune Systems,and the Challenge of Integration
Current Vascular Pharmacology The Role of IRE1 Signaling in the Central Nervous System Diseases
Current Neuropharmacology Dopamine Targeting Drugs for the Treatment of Schizophrenia: Past, Present and Future
Current Topics in Medicinal Chemistry Prevention of Non-immune Mediated Transfusion-related Acute Lung Injury; from Blood Bank to Patient
Current Pharmaceutical Design Agonistic and Antagonistic Bivalent Ligands for Serotonin and Dopamine Receptors Including their Transporters
Current Topics in Medicinal Chemistry New Antipsychotics in Treatment of Mood Instability and Cognitive Perceptual Symptoms in Borderline Personality Disorder
Current Psychopharmacology